We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

52 hedge funds and large institutions have $415M invested in Design Therapeutics in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

4% more funds holding

Funds holding: 50 → 52 (+2)

0.8% more ownership

Funds ownership: 50.05% → 50.85% (+0.8%)

24% less capital invested

Capital invested by funds: $546M → $415M (-$131M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
52
Holders Change
+2
Holders Change %
+4%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
3
Increased
23
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$10M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.99M
3
TD Asset Management
TD Asset Management
Ontario, Canada
+$738K
4
LGM
Logos Global Management
California
+$665K
5
Goldman Sachs
Goldman Sachs
New York
+$566K

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$3.91M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.96M
3
BlackRock
BlackRock
New York
-$1.51M
4
CAM
Cormorant Asset Management
Massachusetts
-$831K
5
Northern Trust
Northern Trust
Illinois
-$211K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.33M +$45.8K +2,756 +3%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$965K +$738K +44,396 +208%
Goldman Sachs
28
Goldman Sachs
New York
$810K +$566K +34,056 +162%
Ensign Peak Advisors
29
Ensign Peak Advisors
Utah
$735K – – –
N
30
Nuveen
North Carolina
$696K -$7.78K -468 -1%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$536K +$49.5K +2,979 +9%
Bank of America
32
Bank of America
North Carolina
$465K +$419K +25,228 +394%
Citigroup
33
Citigroup
New York
$364K +$18.6K +1,118 +5%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$256K – – –
OCA
35
Octagon Capital Advisors
New York
$219K -$3.91M -235,074 -94%
Millennium Management
36
Millennium Management
New York
$208K +$236K +14,169 New
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$172K +$2.29K +138 +1%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$156K +$176K +10,589 New
JP Morgan Chase
39
JP Morgan Chase
New York
$120K +$2.36K +142 +2%
Deutsche Bank
40
Deutsche Bank
Germany
$118K +$249 +15 +0.2%
AIG
41
American International Group
New York
$112K +$1.2K +72 +1%
Morgan Stanley
42
Morgan Stanley
New York
$108K +$112K +6,757 +1,044%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$106K -$189K -11,357 -61%
PSC
44
Piper Sandler & Co
Minnesota
$37K +$41.6K +2,500 New
SO
45
STRS Ohio
Ohio
$29K -$18.3K -1,100 -35%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$23K +$11.1K +668 +72%
Legal & General Group
47
Legal & General Group
United Kingdom
$19K – – –
UBS Group
48
UBS Group
Switzerland
$17K +$10.6K +636 +128%
AIP
49
Ameritas Investment Partners
Nebraska
$16K – – –
TRCT
50
Tower Research Capital (TRC)
New York
$7K -$28K -1,683 -79%
1
2
3

DSGN Hedge Fund Activity: Q3 2021 in Review

52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2021, worth a combined $415M — down 24% from $546M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DSGN positions and 1 closed out — a net gain of 2 holders — while 23 added to existing stakes and 11 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $10M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.91M.

  • 52 institutional investors held Design Therapeutics (DSGN) as of Q3 2021, up from 50 in Q2 2021.
  • Funds reported $415M of Design Therapeutics stock for Q3 2021, down 24% quarter-over-quarter.
  • 3 funds opened new Design Therapeutics positions in Q3 2021 and 1 closed out, a net change of +2 holders.
  • The largest Design Therapeutics buyer in Q3 2021 was EcoR1 Capital, an estimated $10M added.
  • The largest Design Therapeutics seller in Q3 2021 was Octagon Capital Advisors, an estimated $3.91M sold.

Based on aggregated 13F filings for Q3 2021.